Haleon (NYSE:HLN) Cut to "Hold" at Wall Street Zen

Haleon (NYSE:HLN - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Thursday.

Several other research analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. HSBC reiterated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Finally, Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Six equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Haleon has a consensus rating of "Moderate Buy" and an average target price of $12.33.

Haleon Trading Up 0.7%

Shares of NYSE:HLN traded up $0.08 during midday trading on Thursday, hitting $11.22. The company had a trading volume of 10,264,456 shares, compared to its average volume of 12,961,484. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon has a 12 month low of $8.24 and a 12 month high of $11.35. The firm has a fifty day simple moving average of $10.32 and a 200 day simple moving average of $9.92. The stock has a market cap of $50.54 billion, a price-to-earnings ratio of 32.99, a PEG ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. On average, analysts predict that Haleon will post 0.43 EPS for the current year.

Hedge Funds Weigh In On Haleon

A number of large investors have recently bought and sold shares of the company. Bartlett & CO. Wealth Management LLC lifted its position in shares of Haleon by 135.9% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock worth $27,000 after purchasing an additional 1,491 shares in the last quarter. Sierra Ocean LLC acquired a new stake in Haleon in the 4th quarter valued at $26,000. Banque Transatlantique SA bought a new stake in Haleon during the 1st quarter worth about $27,000. Opal Wealth Advisors LLC bought a new stake in Haleon during the 1st quarter worth about $29,000. Finally, Ransom Advisory Ltd acquired a new position in shares of Haleon during the 1st quarter worth about $31,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.